Profusa & NorthView Sponsor I LLC Amend $1.87M Promissory Note

The financial tightrope walk continues for Profusa Inc. (NASDAQ: PFSA), a biotech firm grappling with multiple Nasdaq listing deficiencies and now, a restructured debt agreement. While the news originates from SEC filings and company announcements, the implications ripple outwards, and here in Austin, Texas – a burgeoning hub for biotech and venture capital – it serves as a stark reminder of the risks inherent in the small-cap biotech space. The situation isn’t just about one company; it’s about investor confidence, the health of the local funding ecosystem, and the potential impact on related service providers.

Navigating Nasdaq Deficiencies and Debt Restructuring

Profusa is currently facing an existential threat to its Nasdaq Global Market listing. The company failed to meet the minimum market value of publicly held shares requirement of $15 million by the April 27, 2026 deadline. This adds to pre-existing deficiencies related to the minimum closing bid price of $1.00 and the minimum market value of listed securities of $50 million. The company has until May 5, 2026, to present its case to the Nasdaq Hearings Panel and potentially avoid delisting. This is a critical juncture, and the outcome will significantly impact the company’s future prospects.

To buy itself time and address immediate financial pressures, Profusa has been actively restructuring its debt. On April 24, 2026, the company amended an existing promissory note with NorthView Sponsor I LLC. The outstanding principal on this note now stands at approximately $1.9 million. The amended note is non-interest bearing and matures on December 31, 2026, offering Profusa extended breathing room. A key element of the restructuring involves the note’s convertibility into common stock, with a conversion price set at the greater of $0.35 per share or 95% of the closing price. To mitigate immediate dilution, Profusa has implemented an exchange cap, limiting the issuance of conversion shares to 19.99% of outstanding stock unless shareholder approval is secured. Management is obligated to seek this approval within 90 days and periodically thereafter.

Further demonstrating its efforts to manage its financial obligations, Profusa likewise amended a warrant held by Ascent Partners Fund LLC, allowing the purchase of up to 3.3 million shares at an exercise price of $0.50. These moves, while necessary for survival, highlight the precarious financial position of the company and the challenges it faces in maintaining its listing and funding its operations.

The Austin Biotech Landscape and the Ripple Effect

Here in Austin, the biotech sector is experiencing significant growth, fueled by investments from firms like Dell Medical School and the University of Texas at Austin. The presence of companies like BioLegend and numerous startups creates a dynamic, albeit competitive, environment. Profusa’s struggles, while occurring elsewhere, serve as a cautionary tale for investors and companies operating within this ecosystem. The University of Texas at Austin’s McCombs School of Business, for example, actively teaches courses on venture capital and risk assessment; cases like Profusa’s provide valuable real-world learning opportunities. The Austin Chamber of Commerce also plays a role in attracting and supporting biotech companies, and events like the Texas Life Science Forum are crucial for networking and investment. A high-profile delisting could potentially dampen investor enthusiasm and make it more difficult for smaller biotech firms to secure funding, even those with promising technologies.

The situation also impacts the professional services sector. Law firms specializing in securities law, accounting firms with expertise in forensic accounting, and investor relations firms all benefit from a healthy biotech market. Profusa’s challenges could lead to reduced demand for these services, at least in the short term. The company’s situation underscores the importance of robust financial planning and risk management, areas where specialized consultants can provide valuable assistance.

Navigating the Fallout: A Local Resource Guide for Austin Residents

Given my background in financial risk analysis, and understanding the potential impact of situations like Profusa’s on the Austin community, here are three types of local professionals you should consider consulting if you’ve invested in small-cap biotech stocks or are considering doing so:

Securities Litigation Attorneys

If you believe you’ve been misled by a company’s financial reporting or disclosures, a securities litigation attorney can assess your legal options. Look for firms with a proven track record in representing investors in similar cases and experience with Nasdaq delisting proceedings. Specifically, prioritize attorneys familiar with Section 10(b) and Rule 10b-5 of the Securities Exchange Act of 1934.

Forensic Accounting Firms

These firms specialize in investigating financial irregularities and uncovering hidden liabilities. If you suspect a company’s financial statements are inaccurate or misleading, a forensic accountant can conduct a thorough review and provide an independent assessment. Look for Certified Fraud Examiners (CFEs) on staff and experience with biotech company valuations.

Registered Investment Advisors (RIAs) with Biotech Specialization

A qualified RIA can help you diversify your portfolio, manage risk, and make informed investment decisions. Specifically, seek advisors who have a deep understanding of the biotech industry, its unique challenges, and the regulatory landscape. Verify their fiduciary duty and ensure they operate on a fee-only basis to avoid potential conflicts of interest. Consider advisors who actively monitor SEC filings and Nasdaq announcements.

Ready to find trusted professionals? Browse our complete directory of top-rated financial experts in the Austin area today.